Podcasts about implantable

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Device-Removal, Reinfection, and Mortality After Staphylococcus aureus Bacteremia in Patients With Cardiac Implantable Electronic Devices.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore advances in implantable diabetes technologies, focusing on a novel implantable insulin pump from Portal Diabetes that has received FDA Breakthrough Device designation.Key Timestamps00:00:01 Intro00:00:14 Implantable insulin pumps00:01:06 What is breakthrough status?00:03:00 How the pump works00:03:41 What makes it different from MiniMed?00:07:36 How does it administer insulin?00:09:47 The Twiist pump with EverSense00:13:30 Outro

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In Episode 332 of The Healthy Diabetic Podcast, Coach Ken is joined by Graham for another live, unscripted conversation that blends fitness, diabetes management, and real-world decision making.This episode starts with a surprisingly deep unscripted discussion on exercise selection, and why most people overcomplicate exercise—especially when living with diabetes. From there, the conversation expands into consistency vs optimization, habit-building, insulin sensitivity, and how any form of intentional movement can support blood sugar regulation.The second half of the episode dives into the future of diabetes technology, including closed-loop systems, implantable pumps, glucagon integration, and how innovation is reshaping what “hands-off” diabetes management could look like. The episode wraps with a thoughtful debate on AI in diabetes, research, education, and why human connection will always matter more than automation.This will challenge how you think about fitness, technology, and progress with diabetes.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

Welcome to this week's episode of The Lead. Join HRS Digital Education Committee member and podcast host Danesh Kella, MBBS, FHRS as he welcomes his guests Rahul N Doshi, MD, FHRS and Robert D Schaller, DO, FHRS. They are discussing Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extractions, which was published in the Journal of the American College of Cardiology in October 2025. This article describes the use of mechanical vacuum aspiration systems to debulk large intracardiac vegetations during cardiac implantable electronic device (CIED) extraction, aiming to reduce embolic risk and procedural complications. The authors highlight procedural techniques, patient selection, and safety considerations when combining aspiration with transvenous lead extraction. This approach represents an important adjunctive strategy for managing complex CIED infections with large vegetations.   Learning Objectives Describe the role of mechanical vacuum aspiration in the management of large vegetations during CIED extraction procedures. Identify patient selection criteria and procedural considerations for safely combining vegetation debulking with transvenous lead extraction. Recognize potential risks, benefits, and complications associated with aspiration-assisted extraction in patients with CIED infection.   Article for Discussion: https://www.jacc.org/doi/10.1016/j.jacc.2025.07.043   Article Authors Yury Malyshev, Marc A. Miller, Anelechi Anyanwu, George C. Shaw, Mouhannad Sadek, Seth Newman, Sakshum Chadha, Maryam Saleem, Nana Gegechkori, Abhishek Maan, Daniel Musikantow, Mohit Turagam, William Whang, Joshua Lampert, Jacob Koruth, Srinivas Dukkipati, Eric Neibart, and Vivek Y. Reddy Podcast Contributors Danesh Kella, MBBS, FHRS Rahul N Doshi, MD, FHRS Robert D Schaller, DO, FHRS Host and Contributor Disclosure(s): D. Kella Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum R. Doshi Honoraria/Speaking/Teaching/Consulting: Boston Scientific, Kestra, Inc., Abbott, Impulse Dynamics   R. Schaller   Honoraria/Speaking/Consulting: Medtronic, Boston Scientific, Philips, Cook Medical Research: Abbott Medical   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.  

Commentary by JACC: Clinical Electrophysiology Executive Editor Emile Daoud, MD.

Routine EEG provides a brief snapshot of brain activity and may not capture seizures or epileptiform activity. In this conversation, neurologist Prof. Norman Delanty explains how extended and implantable EEG monitoring can improve assessment of seizure burden, support treatment decisions, and clarify diagnosis and management when short recordings are insufficient. This episode is sponsored by EASEE® by Precisis and had no influence over the editorial content or discussion. Learn more about EASEE® here: https://precisis.de/en   

Paul Goode, President and CEO of Glucotrack, discusses the evolution and future of continuous glucose and continuous blood glucose monitoring for people with diabetes, as well as opportunities for implantable CMG monitors. In addition to convenience and comfort, the Glucotrack implantable CGM monitor is designed to be more accurate and measure blood glucose. This approach eliminates the lag time associated with wearable CGMs that measure interstitial fluid, enabling faster, more effective treatment decisions.   Paul explains, "When you look at the market penetration of CGM in the US, even for those who are covered with insurance, because it is a standard of care in a large portion of patients with diabetes, it's still only a little over 50%. And when you try to understand why, it's because the technology works well, it's pretty accurate, and it helps patients. Market research shows that it's a collection of various reasons."   "When we realized that a large majority of the problems with use of current CGMs, whether people are using them, or people don't want to use them, a lot of these, let's call them hassle factors or discomfort factors, were because it was a wearable product. So we said, well, let's go inside the body, and that resolves almost all of those types of problems."   "Then we said, well, if we're in the body, we can also measure the glucose that's in the blood, actually measure blood glucose. Most folks don't realize that many do, but many don't, that CGM, the wearable CGMs, measure the interstitial fluid and not the actual blood glucose. And typically that's not a problem. There is a time lag between blood glucose and interstitial fluid, with interstitial fluid lagging behind anywhere from 10 to 20 minutes. But that's usually only a problem during rapid rates of change, for example, when one is eating, exercising, or sick. " #Glucotrack #DiabetesTech #MedicalDevices #ContinuousGlucoseMonitoring #HealthcareInnovation #DiabetesManagement #ImplantableTech #BloodGlucose #CGM #MedTech #DiabetesCare #HealthTech glucotrack.com Download the transcript here

Paul Goode, President and CEO of Glucotrack, discusses the evolution and future of continuous glucose and continuous blood glucose monitoring for people with diabetes, as well as opportunities for implantable CMG monitors. In addition to convenience and comfort, the Glucotrack implantable CGM monitor is designed to be more accurate and measure blood glucose. This approach eliminates the lag time associated with wearable CGMs that measure interstitial fluid, enabling faster, more effective treatment decisions.   Paul explains, "When you look at the market penetration of CGM in the US, even for those who are covered with insurance, because it is a standard of care in a large portion of patients with diabetes, it's still only a little over 50%. And when you try to understand why, it's because the technology works well, it's pretty accurate, and it helps patients. Market research shows that it's a collection of various reasons."   "When we realized that a large majority of the problems with use of current CGMs, whether people are using them, or people don't want to use them, a lot of these, let's call them hassle factors or discomfort factors, were because it was a wearable product. So we said, well, let's go inside the body, and that resolves almost all of those types of problems."   "Then we said, well, if we're in the body, we can also measure the glucose that's in the blood, actually measure blood glucose. Most folks don't realize that many do, but many don't, that CGM, the wearable CGMs, measure the interstitial fluid and not the actual blood glucose. And typically that's not a problem. There is a time lag between blood glucose and interstitial fluid, with interstitial fluid lagging behind anywhere from 10 to 20 minutes. But that's usually only a problem during rapid rates of change, for example, when one is eating, exercising, or sick. " #Glucotrack #DiabetesTech #MedicalDevices #ContinuousGlucoseMonitoring #HealthcareInnovation #DiabetesManagement #ImplantableTech #BloodGlucose #CGM #MedTech #DiabetesCare #HealthTech glucotrack.com Listen to the podcast here

Dr Steve, Lexi and Dr Scott Discuss: Unexplained circumstances in medicine Nursing home smell explained (the answer will surprise you) Implantable defibrillators Food and anxiety Lucid Dreaming from GaaaLaaaGaaaa Please visit: ⁠⁠⁠STUFF.DOCTORSTEVE.COM⁠⁠⁠ (for dabblegames at cost and more!) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠simplyherbals.net/cbd-sinus-rinse⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (the best he's ever made. Seriously.) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/weirdmedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/weirdmedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠fightthedabbler.com⁠⁠⁠ (help Karl and Shuli win their LOLsuit) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@weirdmedicine ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠(click JOIN and ACCEPT GIFTED MEMBERSHIPS. Join the "Fluid Family" for live recordings!) CHECK OUT THE ROADIE COACH stringed instrument trainer! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠roadie.doctorsteve.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (the greatest gift for a guitarist or bassist! The robotic tuner!) see it here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stuff.doctorsteve.com/#roadie⁠⁠⁠⁠⁠⁠⁠ GET YOUR COPY OF "WET BRAIN: THE GAME OF TROLLS AND LOSERS!" get it here: ⁠⁠⁠⁠⁠⁠⁠ dabblegames.myshopify.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (a most-fun party game!) DABBLEDICE: Second Edition available NOW! Only $3.50 plus shipping! each shipment comes with some awful tchotchke! we're getting out of the dabbleverse business so everything is sold at COST Also don't forget: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cameo.com/weirdmedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Book your old pal right now because he's cheap! "FLUID!") Most importantly! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CHECK US OUT ON PATREON! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ALL NEW CONTENT! Robert Kelly, Mark Normand, Jim Norton, Gregg Hughes, Anthony Cumia, Joe DeRosa, Pete Davidson, Geno Bisconte, Cassie Black ("Safe Slut"). Stuff you will never hear on the main show ;-) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Commentary by Dr. Jian'an Wang.

Dr. Centor discusses complications of cardiac implantable electronic devices with Dr. Peter Zimetbaum.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Implantable Cardioverter Defibrillator Lead Dysfunction After Left Ventricular Assist Device Implantation.

With Domenico Filomena, Polyclinic Umberto I, Rome - Italy and Luciano Agati Sapienza, University of Rome, Rome - Italy. Link to European Heart Journal paper Link to European Heart Journal editorial

Technology is transforming heart failure care. From pacemakers to defibrillators and beyond, learn how implantable devices work, what to expect and how they're changing lives for the better. Featuring Asghar Fakhri, MD, associate chair of cardiology at UM Baltimore Washington Medical Center and a cardiologist at UM Baltimore Washington Heart Associates.  For more information about Dr. Fakhri, visit https://www.umms.org/find-a-doctor/profiles/dr-asghar-fakhri-md-1265621031.

Dr. Kenneth Ellenbogen, Deputy Editor of JACC: Clinical Electrophysiology, discusses Mental Disorders Following Implantable Cardioverter-Defibrillator Therapy: Incidence and Prognostic Implications in a Nationwide Cohort Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Role of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices.

Commentary by Dr.  Jian'an Wang.

On The Show Today: Plus: What defines the “eras” of Distorted View? (Hint: all of them are terrible). Implantable sleep apnea devices vs. CPAP masks. GLP-1 shots as the perfect scam: insurance-funded weight loss! Our New PO Box Address! Distorted ViewPO Box 36268Cincinnati, OH 45236 The post Why Is My Sperm Hole Twitching? first appeared on Distorted View Daily.

CardioNerds guest host Dr. Colin Blumenthal joins Dr. Juma Bin Firos and Dr. Aishwarya Verma from the Trinity Health Livonia Hospital to discuss a fascinating case involving malignant ventricular arrhythmias. Expert commentary is provided by Dr. Mohammed Ali-Jazayeri. Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes.  This case explores the puzzling presentation of exercise-induced ventricular tachycardia in a young, otherwise healthy male who suffered recurrent out-of-hospital cardiac arrests. With no traditional risk factors and an unremarkable ischemic workup, the challenge lay in uncovering the underlying cause of his malignant arrhythmias. Electrophysiology studies and advanced imaging played a pivotal role in systematically narrowing the differentials, revealing an unexpected arrhythmogenic substrate. This episode delves into the diagnostic dilemma, the role of EP testing, and the critical decision-making surrounding ICD placement in a patient with a concealed but life-threatening condition.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls- Malignant Ventricular Arrhythmias This case highlights the challenges and importance of diagnosing and managing ventricular arrhythmias in young, seemingly healthy individuals. Here are five key takeaways from the episode:  Electrophysiology (EP) studies play a crucial role in identifying arrhythmogenic substrates in patients with exercise-induced ventricular tachycardia (VT) without obvious structural heart disease. In this case, substrate mapping revealed late abnormal ventricular afterdepolarizations in the basal inferior left ventricle, providing valuable insights into the underlying mechanism.  Cardiac MRI can be a powerful tool for detecting subtle myocardial abnormalities. The subepicardial late gadolinium enhancement (LGE) in the lateral and inferior LV walls suggested an underlying myocardial process, even when other imaging modalities appeared normal.  The VT morphology can provide clues about the underlying mechanism. In this case, the right bundle branch block pattern with a northwest axis and shifting exit sites pointed towards a scar-mediated mechanism rather than a channelopathy or idiopathic VT.  Implantable cardioverter-defibrillator (ICD) placement is crucial for secondary prevention of sudden cardiac death (SCD) in patients with malignant ventricular arrhythmias, even in young individuals. The patient's initial deferral of ICD implantation highlights the importance of shared decision-making and patient education in these complex cases.  "Scar-mediated VT introduces the risk of new arrhythmogenic substrates over time, reinforcing the need for ICD therapy even when catheter ablation is considered." This pearl emphasizes the dynamic nature of the arrhythmogenic substrate and the importance of long-term risk mitigation strategies.  Notes - Malignant Ventricular Arrhythmias Notes were drafted by Juma Bin Firos.  1. What underlying pathologies cause ventricular arrhythmias in young patients without overt structural heart disease? Myocardial fibrosis: Detected via late gadolinium enhancement (LGE) on cardiac MRI Present in 38% of nonischemic cardiomyopathy cases Increases sudden cardiac death (SCD) risk 5-fold Often localized to subepicardial regions, particularly in the inferolateral left ventricle (LV) May precede overt systolic dysfunction by years Subclinical cardiomyopathy: 67% of young VT patients show subtle cardiac dysfunction Suggests VT may be the first manifestation of cardiomyopathy

Tune in to The Implantable Lens Insider and become part of the conversation shaping the future of vision correction. Your expertise as an optometrist is crucial in guiding patients toward the clarity that implantable lenses can offer. Join us as we explore the exciting possibilities and navigate the landscape of lens implantation together.

Too busy to read The Lens? Listen to our weekly summary here! In this week's episode we discuss:Implantable devices such as EYEMATE-SC show promise in safely and accurately measuring intraocular pressure without the assistance of a clinician. There is promise in using machine learning algorithms in glaucoma risk assessment as an objective tool for measuring retinal nerve fiber layer thickness from optic disc images.Hormonal contraceptive use confers a higher relative risk of retinal vein occlusion, though the relative risk of retinal vein occlusions is low.

Sandeep A Saha, MD, MS, FHRS, Oregon Heart Center PC is joined by Saket Sanghai, MD, FHRS, Oregon Health & Science University, and Naga Venkata Krishna Chand Pothineni, MD, Kansas City Heart Rhythm Institute, to discuss how the study evaluated the effectiveness of implantable loop recorders (ILRs) in detecting arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Traditional monitoring methods, like Holter monitors, often miss intermittent arrhythmic events in HCM patients. ILRs, offering continuous long-term monitoring, were found to identify clinically significant arrhythmias that might otherwise go undetected. The findings suggest that ILRs can play a crucial role in risk stratification and management of HCM patients, potentially guiding decisions regarding interventions such as implantable cardioverter-defibrillator (ICD) implantation. Overall, ILRs enhance the detection of arrhythmias in HCM, leading to improved patient care.    https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2025.03.005 Host Disclosure(s): S. Saha: Honoraria/Speaking/Consulting Fee: Medtronic Membership on Advisory Committees: Medtronic Inc. Contributor Disclosure(s): S. Sanghai: Research: Siemens Healthcare Stocks (Publicly Traded): Apple Inc., Alphabet Inc., Amazon Stock Options (Publicly Traded): Intel K. Pothineni: Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Boston Scientific

Association Between COVID-19 Vaccination and Atrial Arrhythmias in Individuals with Cardiac Implantable Electronic Devices   Guest: Malini Madhavan, M.B.B.S. Host: Anthony H. Kashou, M.D.   In a study of over 7000 individuals with a cardiac implanted device in the Biotronik CERTITUDE registry, the burden of device detected AF was noted to be higher in the 3 months after covid vaccination compared to the 3 months preceding vaccination. A similar trend was observed for Influenza vaccinated individuals. However, when comparing a propensity matched group of controls without COVID vaccination, the trend towards increased burden of AF was similar in the 2 groups. This led the authors to conclude that the observed increase in AF burden represents the natural progression of AF risk rather than vaccine related changes.   Topics Discussed: The study of atrial fibrillation burden after COVID vaccination, including the conclusion. How the incidence of AF after COVID 19 vaccination compares to that after influenza vaccination. Other studies that have investigated arrhythmia occurrence after COVID vaccination. Safety for patients with cardiovascular disease to get vaccinated for COVID 19. References: https://www.heartrhythmjournal.com/article/S1547-5271(22)00914-6/fulltext https://onlinelibrary.wiley.com/doi/epdf/10.1111/jce.16372 https://pmc.ncbi.nlm.nih.gov/articles/PMC9175153/#:~:text=A%20total%20of%202611%20events,COVID%2D19%20vaccine%20doses%20administered Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Join host Michael S. Lloyd, MD,FHRS and episode participants Karim Benali, MD, PhD and Reinoud Knops, MD, PhD as they discuss this recent article that focuses on unique aspects of implantable defibrillators as experienced by young patients. The team gathered in person for this lively discussion at EHRA 2025 in Vienna. Bonus video footage of the episode is available on heartrhythm365.org. https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/10.1161/CIRCEP.124.013365 Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific   Contributor Disclosure(s): K. Benali: Nothing to disclose. R. Knops: Honoraria/Speaking/Consulting: Boston Scientific, Metronic, Inc., Cairdac, Abbott Membership on Advisory Committees: Kestra, Inc.

The wide array of cardiovascular implantable electronic devices (CIEDs) s may lead to confusion as to which one to use in what circumstances. Differentiating defibrillators, pacemakers, and loop recorders--as well as accessing and utilizing the collected data--is covered by guest Erin Nordstrom, BSN, RN, PHN, CV-B. Related PCNA courses:Choosing the Right Cardiac Pacing Device: https://pcna.net/online-course/choosing-the-right-cardiac-pacing-device-heart-failure-interventions/ 12-Lead ECG in the Clinical Setting: https://pcna.net/online-course/interpreting-and-applying-the-12-lead-ecg-in-clinical-settings/Managment of Atrial Fibrillation: https://pcna.net/online-course/management-of-atrial-fibrillation-from-a-to-z/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hearing technology is evolving, and fully implantable devices are becoming a reality. In this discussion, Brent Lucas, CEO of Envoy Medical, joins Shari Eberts to talk about the company's fully implantable hearing solutions, including the Esteem active middle ear implant and the Acclaim fully implantable cochlear implant, which is currently in clinical trials. Unlike traditional hearing aids and cochlear implants, these devices do not require an external component, allowing users to hear 24/7, even while sleeping or showering.The conversation also explores key trends in hearing technology, including increased competition and innovation in the space. With major tech players like Apple entering the market and advancements in consumer hearing solutions, the landscape of hearing care is shifting. Brent discusses how greater competition, choice, and awareness can help address hearing loss stigma and ensure that individuals have more options beyond traditional hearing aids.Additionally, Brent highlights the Hearing Device Coverage Clarification Act, legislation aimed at improving insurance coverage for fully implantable hearing devices. He emphasizes the importance of consumer advocacy and encourages individuals to research all available hearing solutions to find the best option for their unique needs.Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter): https://www.linkedin.com/company/this-week-in-hearing/ https://twitter.com/WeekinHearing

Our guest today is Evelyn Gamble.  Evelyn is a dedicated healthcare worker and passionate heart disease advocate. With a deep commitment to improving health outcomes, Evelyn uses her personal and professional experiences to raise awareness about heart health, particularly for young adults. As a strong voice for change, she aims to inspire others to take proactive steps in managing their heart health and to advocate for better care and resources for those affected by heart disease.     Definition: A heart arrhythmia, also known as a cardiac arrhythmia, is an abnormal rhythm of the heart. It occurs when the electrical impulses that control the heart's contractions do not function properly.    Causes:    Heart arrhythmias can be caused by a wide range of factors, including:    Heart disease (e.g., coronary artery disease, heart failure) Electrolyte imbalances (e.g., low potassium or magnesium) Certain medications (e.g., stimulants, caffeine) Thyroid disorders Damage to the Vagus Nerve Stress Genetics    Types:    There are many different types of heart arrhythmias, which can be classified based on the rate and rhythm of the heart:    Tachycardia: A rapid heart rate (over 100 beats per minute)    Bradycardia: A slow heart rate (under 60 beats per minute)    Atrial fibrillation: A quivering or irregular rhythm of the upper chambers of the heart (atria)    Ventricular fibrillation: A life-threatening rhythm where the lower chambers of the heart (ventricles) contract irregularly and chaotically    Premature beats: Extra heartbeats that occur early in the rhythm    Symptoms:    Some people with heart arrhythmias may not experience any symptoms. Others may have symptoms such as:    Palpitations (feeling like the heart is racing or fluttering), Chest pain or discomfort, Dizziness or lightheadedness, Fainting, and Shortness of breath.    Diagnosis and Treatment:    To diagnose a heart arrhythmia, your doctor will likely perform a physical exam, ask about your medical history, and take an electrocardiogram (ECG). Treatment options depend on the type and severity of the arrhythmia and may include:    Medications (e.g., beta-blockers, antiarrhythmics) Lifestyle changes (e.g., exercise, stress management) Surgery (e.g., ablation procedure) Implantable devices (e.g., pacemakers, defibrillators)    Outlook: The outlook for people with heart arrhythmias varies depending on the underlying cause and severity of the condition.

Imagine a world where the medical devices implanted in the body could communicate with doctors, providing vital data that could change the course of treatment and recovery. As technology advances, this scenario is becoming a reality. This breakthrough in medical technology not only promises enhanced patient outcomes but also pioneers a new approach to postoperative care, where data leads the way. In this week's episode, sponsored by Physician Growth Accelerator, we welcome Bill Hunter, President and CEO of Canary Medical, to discuss how his team is pioneering the transformation of medical devices into data-communicating tools. Bill shares insights on the development of smart implants that offer real-time feedback to both healthcare providers and patients, drastically altering expectations and outcomes in medical treatments. Join us as we explore the innovations driving this change and the future possibilities of implant technology. What we discuss in the episode: How implantable devices are being designed to communicate health data The impact of real-time data feedback from implants on post-operative care Future directions for smart implants in medical technology Case studies demonstrating the effectiveness of data-driven patient care Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator Canary Medical Social Media:  Connect with Bill on LinkedIn Connect with Zed on LinkedIn Connect with Clark on LinkedIn

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that uses machine learning to predict mortality and hospitalization risks in patients with implantable cardioverter defibrillators (ICDs). By leveraging large datasets and time-varying ICD data, the study developed a robust predictive model, though challenges remain regarding data gaps and its applicability to diverse patient populations.

Brent Lucas, CEO of Envoy Medical, highlights the lack of innovation in hearing aids and the need to better address hearing health. Envoy has developed fully implanted hearing devices that provide 24/7 hearing assistance without the need for daily recharging of the battery.  With the introduction of over-the-counter hearing aids and the advanced Apple AirPods Pro 2, customer options have been expanded, making it easier to address some forms of hearing loss. Implanted devices eliminate the limitations of external hearing aids and reduce the impact of hearing loss on their daily lives. Brent explains, "Part of the problem in the hearing loss industry has been that it's not well understood. So there has not been a great deal of competition and innovation in the hearing loss world. Most of us have thought about hearing loss and how it's addressed by looking to our grandparents, the elders. Plenty of people joke about our dads or our grandfathers not being able to hear our grandmothers. When I tell people I'm in the hearing industry, the first thing that they say is, I can't hear you. And I always fall for it. And I say, I'm in the hearing industry, and they come clean that it was a joke. At the end of the day, there are unmet needs in finding solutions for people that are not just the status quo. That's really where Envoy Medical is building products that are fully implanted, in a sense, a better life because they're not tied to their hearing loss." "Right now, the current solutions on the market are all external products that need to be taken off at night or around water in the shower, during strenuous activity, working out, sweating too much, that sort of thing. You have to take your external device off. Our devices are fully implanted, meaning you can be capable of hearing 24/7, hearing all day, every day. We think that's the right thing to do for a patient because your hearing loss, after all, is a 24-hour problem. It shouldn't be that your solution is only on for part of the day."  #EnvoyMedical #HearingLoss #Acclaim #HearingAids #CochlearImplant $COCH #HearingHealth  envoymedical.com Download the transcript here

Brent Lucas, CEO of Envoy Medical, highlights the lack of innovation in hearing aids and the need to better address hearing health. Envoy has developed fully implanted hearing devices that provide 24/7 hearing assistance without the need for daily recharging of the battery.  With the introduction of over-the-counter hearing aids and the advanced Apple AirPods Pro 2, customer options have been expanded, making it easier to address some forms of hearing loss. Implanted devices eliminate the limitations of external hearing aids and reduce the impact of hearing loss on their daily lives. Brent explains, "Part of the problem in the hearing loss industry has been that it's not well understood. So there has not been a great deal of competition and innovation in the hearing loss world. Most of us have thought about hearing loss and how it's addressed by looking to our grandparents, the elders. Plenty of people joke about our dads or our grandfathers not being able to hear our grandmothers. When I tell people I'm in the hearing industry, the first thing that they say is, I can't hear you. And I always fall for it. And I say, I'm in the hearing industry, and they come clean that it was a joke. At the end of the day, there are unmet needs in finding solutions for people that are not just the status quo. That's really where Envoy Medical is building products that are fully implanted, in a sense, a better life because they're not tied to their hearing loss." "Right now, the current solutions on the market are all external products that need to be taken off at night or around water in the shower, during strenuous activity, working out, sweating too much, that sort of thing. You have to take your external device off. Our devices are fully implanted, meaning you can be capable of hearing 24/7, hearing all day, every day. We think that's the right thing to do for a patient because your hearing loss, after all, is a 24-hour problem. It shouldn't be that your solution is only on for part of the day."  #EnvoyMedical #HearingLoss #Acclaim #HearingAids #CochlearImplant $COCH #HearingHealth  envoymedical.com Listen to the podcast here

Send us a textIt's already Episode 20 of Season 2 as we roll into winter 2024.Again this week the boy's are lucky to have two Guests Bethany Keime and Charlie Kirkman, both have different heart conditions, Bathany and twin sister Hannah both suffer from Hypertropic Cardiomyopathy whilst Charlie has Arrhythmia.Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles.This is  is most often caused by abnormal genes in the heart muscle. These genes cause the walls of the heart chamber (left ventricle) to become thicker than normal. The thickened walls may become stiff and this can reduce the amount of blood taken in and pumped out to the body with each heartbeat.How is hypertrophic cardiomyopathy treated?Activity limits. ...Preventing dehydration. ...Medicines to treat shortness of breath and chest pain. ...Medicines to help prevent abnormal heart rhythms. ...Anticoagulants. ...Septal myectomy. ...Alcohol septal ablation. ...Implantable cardioverter defibrillator (ICD).An Arrhythmia, or irregular heartbeat, is a problem with the rhythm or rate of your heartbeat. Your heart may beat too quickly, too slowly, or with an irregular rhythm. It is normal for your heart rate to speed up during physical activity and to slow down while resting or sleeping but with Arrhythmia this can be irregular anytime.While Arrhythmias can be a serious condition that can affect your health, there are also treatments available to help. By following a treatment plan and making heart healthy lifestyle changes, you can learn how to live with a cardiac arrhythmia.In today's Interview Bethany & Charlie tell us openly and honestly about their conditions from diagnosis to how the deal with it today and in everyday life.Bethany & sister Hannah are two remarkable twins who have taken this illness head on and realised there are others like themselves undiagnosed. Their experience as young teenagers soon discovered there was little information available and resorted to Google to explore their condition. Social Media Patient Community did not exist, so Bethany & Hannah set about correcting this by starting their own Social media presence "Heart Charged" in hope to reach out to those with this condition and those still to be diagnosed.They made us aware that as young women it was hard to get healthcare professionals to take them seriously with their health issues, simply sidelining them and saying "It's all part of growing up as a young Women"  It wasn't until a member of the family discovered they had hypertrophic cardiomyopathy that both Bethany & Hannah were then checked for this Condition.These young women have gone from strength to strength and this is how they met Charlie through Their social media connections and recent success with the "Sudden Cardiac Art" Exhibition in the UK, now destined for Southern California.#getheartcharged#charliekirkman# Stroke# Subarachnoid hemorrhage#Mediastinal Germ Cell Tumour#Prostate Cancer#Bronchiectasis#CharcotmarietoothDisease#Emphysema#The after life#Ghosts#Spirts#Ouija boards#Mediums#Psychics#Reincarnation#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#HealthcareCheck out our website at www.whostomanddick.com

Dr. Robert Gereau a professor of anesthesiology at Wash U School of Medicine and director of Wash U's Pain Center joins KMOX Health Editor Fred Bodimer.

In today's episode, I sat down with Paul, T1D and endurance enthusiast. Paul and I talk about growing up at a early age with Diabetes, pre-technology. We also discuss Eversense, the implantable CGM and Affrezza, inhaled insulin. Paul's InstagramCoach Ken's Resources:Website: www.simplifyingdiabetes.comNewsletter Sign Up"More Than A1C" - My Signature Coaching ProgramThe Diabetes Nutrition Master CourseThe 5-Pillars Of Diabetes Success WorksheetSupport & Donate To The PodcastThe T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for Diabetes research. Once enrolled, Registry participants have the opportunity to sign up for other studies on various topics related to type 1 diabetes.You can make an impact on the future of Diabetes now! Fill out an online  survey and gain access to tons of new research and the online portal. It only takes 10-15 minutes.Don't forget to check out Ancient Bliss an herbal supplement company.Use Discount Code KEN20 for 20% off at check out.Have a question, send me a DM or email. I'd love to connect and answer any questions you have.You can find the show  on any platform you listen to your podcasts!Don't forget to click on that subscribe button and leave a 5-star review, so you're notified when new episode drop every week.Questions about diabetes, don't hesitate to reach out:Instagram: @CoachK3NInstagram: @thehealthydiabeticpodTwitter: @thehealthydpodTik Tok: @thehealthydiabeticpodFacebook: @Simplifying Life With DiabetesEmail: ken@simplifyingdiabetes.comPodcast Disclaimer: Nothing that you hear on The Healthy Diabetic Podcast should be considered medical advice or otherwise; please always consult your medical TEAM before making any changes to your Diabetes management.Support the show

In this episode, Dr. Valentin Fuster discusses a comprehensive review on the challenges and considerations of using implantable cardiography devices in patients with advanced chronic kidney disease and heart failure. Highlighting key findings from Dr. Cecilia Barca's research, he explores the nuanced interplay between these conditions and device efficacy, emphasizing the need for tailored patient evaluations and future studies to improve outcomes.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study looks at insulin needs in men vs women, updates on stem cell transplants and a new look at COVID 19 and T1D plus a fully implantable CGM is announced. We'll also tell you about a T1D athlete drafted to the MLB. Lots more in this week's episode, full transcipt below.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Do men and women have different insulin requirements? A new study conducted across Europe says yes – women overall need less. Published in the Journal of Diabetes Science and Technology this looked at over 9,000 adults with type 1 diabetes using data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop pump system. In this study, women needed 14-percent less insulin overall than men. These researchers say these findings have important implications for the practical management of insulin therapy and highlight the necessity of considering gender as a crucial factor in diabetes treatment. The treatment guidelines provided by American and European Diabetes Societies do not currently have gender-specific recommendations for insulin-weight ratios. The co-founder and Chief Scientific and Technical Officer for Diabeloop. “This study also highlights the capacity to discover new insights from big-data analysis of real-world data.” *Insulin Requirements According to Gender and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery, https://doi.org/10.1177/19322968241252366). https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/27419187/diabeloop-study-reveals-significative-gender-differences-in-insulin-requirements-for-type-1-diabetes-patients/   XX New drug therapy in those lucky diabetic mice boosted insulin-producing cells by 700% over three months, effectively reversing the disease. Scientists at Mount Sinai and City of Hope have been able to grow new beta cells in the body, in a matter of months. The therapy involved a combination of two drugs: one is harmine, a natural molecule found in certain plants, which works to inhibit an enzyme called DYRK1A found in beta cells. The second is a GLP1 receptor agonist. The latter is a class of diabetes drug that includes Ozempic, The researchers tested the therapy in mouse models of type 1 and 2 diabetes.. The signs of the disease quickly reversed, and stayed that way even a month after stopping the treatment.   The results are intriguing, but of course being an animal study means there's still much more work to be done before it could find clinical use. So far, harmine alone has recently undergone a phase 1 clinical trial in humans to test its safety and tolerability, while other DYRK1A inhibitors are planned for trials in humans next year. https://newatlas.com/medical/diabetes-reversing-drug-boosts-insulin-producing-cells/ XX Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. New info from Vertex shows that of a total 17 patients who received a full dose of their  investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880), three, thus far, have achieved the primary study efficacy endpoint of elimination of severe hypoglycemic episodes with A1c < 7% at 1 year and the secondary endpoint of insulin independence. Others are on the same trajectory, Piotr Witkowski, MD, PhD, professor of surgery at The University of Chicago, Chicago, said at the recent American Diabetes Association (ADA) 84th Scientific Sessions. In his presentation, Witkowski also provided details about the deaths of two study participants that the company had announced in January 2024, neither of which were related to the VX-880 product. In fact, there have been no severe adverse events related to the product itself, with most due to either the infusion procedure or the immunosuppression. "These data highlight the curative potential of VX-880 in people living with type 1 diabetes and support further evaluation of VX-880 toward pivotal development," Witkowski said. For now, patients selected for the study are those who experience frequent severe hypoglycemia deemed to be a greater risk to the patient than that of immunosuppression. However, Ahn pointed out, "With VX-880, the obvious fly in the ointment is the need for immunosuppression which carries significant risk…There are multiple solutions being proposed, but we are still waiting for data as promising as the initial Vertex data is on that front." https://www.medscape.com/viewarticle/stem-cell-derived-islets-continue-show-benefit-t1d-2024a1000cx1 XX Still lots of COVID studies coming in about type 1. A German study suggests COVID 19 may speed up progression of existing but presymptomatic T1D in kids. These researchers had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years. They noticed an increase in the numbers of Incidence of clinical type 1 diabetes nearly doubled after the pandemic started. "We know that the virus can infect the pancreatic islets so it could be causing damage or change in the beta cells that make insulin," said Ziegler when discussing possible mechanisms behind this association. "Second, there is generalized inflammation during the infection and there may be a stimulation of the immune response. Third, there could be metabolic stress from the infection that affects the beta cells that make insulin. To dive into this topic, youth were identified in the German Fr1da-screening program from 2015 to 2023. All patients had presymptomatic diabetes defined as persistent, confirmed positive results for two or more islet autoantibodies. Their progression was monitored at 3- to 6-month intervals. Clinical type 1 diabetes was defined according to American Diabetes Association   COVID infection was either self-reported via the family or identified with SARS-CoV-2 antibodies were confirmed in blood samples collected at study visits.   Vaccination against COVID-19 may be one way to protect presymptomatic type 1 diabetes youth from progression, Ziegler added. She said her group is currently testing whether COVID-19 vaccination can reduce new-onset, presymptomatic type 1 diabetes in a clinical trial  of children with genetic risk factors for the condition. https://www.medpagetoday.com/endocrinology/type1diabetes/111084 XX The FDA says no – for now - to Novo Nordisk's weekly insulin.  This has been approved in Canada and should be available there shortly. But the FDA says it wants more information related to the manufacturing process and the type 1 diabetes indication to complete the review. Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps. The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-novo-nordisks-weekly-insulin-2024-07-10/ XX A couple of weeks ago we spoke to the attorneys taking on CGM monitronig in schools. They've helped a family in Connecticut and set a precdent.  A child with autism and diabetes was not getting reasonable accommodations under the federal Americans with Disabilities Act in a public preschool program. I'll link up the press release from the DOJ but this family wasn't getting any support and it just wasn't safe. The lawyers here tell me the ruling and settlement is just going to help them going forward as they try to make schools complient with CGM as a reasonable  accomodatin. https://www.justice.gov/usao-ct/pr/aba-therapy-provider-make-changes-comply-americans-disabilities-act   XX Ozempic could lower the risk of dementia and a range of other mental problems compared with other existing treatments for patients with diabetes. What's more, researchers found that Ozempic cut nicotine dependence in those patients.   This study relied on medical records from more than 100,000 U.S. diabetes patients, including more than 20,000 who were prescribed semaglutide between December 2017 and May 2021. After a year, patients who took Ozempic had a 48% lower risk of developing dementia than those on Januvia. The risk in Ozempic patients was also 37% lower than those who took Glucotrol and 9% lower than those on Jardiance. Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. But the authors emphasized that the analysis is observational. The results need to be replicated in a controlled trial that assigns patients to randomly take Ozempic and the other drugs, according to Dr. Max Taquet, another Oxford clinical lecturer and senior study author. https://www.cnbc.com/2024/07/16/healthy-returns-ozempic-may-lower-dementia-risk-nicotine-use.html XX   Edgepark Commercial XX The Omnipod 5 with Dexcom G7 integration is now available through select pharmacies with full availability expected in the fall.   The System uses new Pods that are compatible with both Dexcom G6 and G7, but the prescription code will stay the same as the current Omnipod 5 Pods. This means the community will have similar insurance coverage and access to what they have with Omnipod 5 today.   If you're looking to start on Omnipod 5 and you're currently using Dexcom G7, your doctor will need to send a prescription for both the Omnipod 5 Intro Kit and Omnipod 5 Pods, compatible with Dexcom G6-G7, to ASPN Pharmacies.   You can learn more at https://www.omnipod.com/innovation/dexcom-g7.   If you are already using Omnipod 5, you will get the new Pods compatible with Dexcom G6 and G7 through your Pod refills. You do not need a new prescription. The week of July 29th, you will receive a free software update for the Omnipod 5 App to your Controller or compatible Android smartphone which is needed to use the System with Dexcom G7. Accept the update. We recommend you continue to use your current Omnipod 5 Pods and Dexcom G6 supplies until the new Pods compatible with Omnipod 5 with Dexcom G6-G7 are available at your preferred pharmacy.   We'll email our users when the new Pods are available in most pharmacies.   You can learn more at https://www.omnipod.com/innovation/new-compatible-devices   XX Big promises about long-term implantable blood glucose monitor from a company called Focus. They say they're partnering with Glucotrack to quote - transform how people with diabetes interact with their condition. They're not calling this a CGM – rather it's a CBGM, continuous blood glucose monitor because it will measure glucose levels in blood, not in interstital fluid like CGMs do. They company says this is a fully subdermal location, with no external wearable. In preclinical studies, the CBGM has a MARD of 4.7% at day 90. That is MUCH lower than CGMs on the market – Dexcom and Libre are in the low 8s right now. BUT.. it hasn't been fully tested in people yet. Human clinical trials are set to start later this year. https://www.drugdeliverybusiness.com/focus-collaborates-glucotrack-implantable-cbgm/ XX Big congrats to Jamie Ferrer (Chy-may Fer-rare) On Monday, Ferrer's dream was realized when the Twins selected the Florida State outfielder in the fourth round (No. 126 overall) during Day 2 of the MLB Draft. Minnesota vice president of amateur scouting Sean Johnson said the club had its eyes on Ferrer since high school. “Recently, I was in Orlando at a conference called, “Friends for Life with CWD [Children with Diabetes],” and we had an event that was a sports day. … Kids would come up to me and either them or their families would ask me how I dealt with this [or that],” Ferrer said. “And seeing their faces light up whenever I said I was diagnosed at three and I played college baseball. … You hear people tell you no and that you can't do this because you have Type 1 diabetes … So why not inspire as many people as I can?”   “I'm super proud of being a Type 1 athlete, and it's something that I'll never shy away from talking about or showing off my insulin pump because it's who I am and it's something that I've had to deal with my entire life.” https://www.mlb.com/news/jaime-ferrer-selected-no-126-overall-by-twins-in-2024-mlb-draft XX Join us again soon!

Broadcast from KSQD, Santa Cruz on 7-11-2024 Dr. Dawn answers a caller's question about vitamin D supplementation, explaining its importance for bone health, mood regulation, and immune function. She discusses the physiological processes involving vitamin D and recommends getting blood levels checked. A second caller asks about the safety of Stevia as a sweetener. Dr. Dawn explains the importance of examining original sources for health claims and discusses the challenges of determining causality in nutrition studies. She compares various artificial sweeteners and suggests moderation in their use. Dr. Dawn provides a health alert about a measles exposure in Santa Cruz, describing symptoms to watch for and emphasizing the importance of vaccination. She shares personal anecdotes about the dangers of measles. An email from a listener about atrial fibrillation is addressed. Dr. Dawn discusses the risks associated with atrial fibrillation, blood thinners, and the Watchman device. She emphasizes the importance of stress reduction and suggests alternatives to invasive procedures. Dr. Dawn comments on a recent retraction of a key Alzheimer's study, discussing the implications for Alzheimer's research and treatment development. A new development in baby formula is discussed, involving genetically modified plants producing human milk oligosaccharides for improved infant nutrition. Dr. Dawn responds to an email about lipoprotein A and cardiovascular risk, discussing risk factors, the importance of inflammation reduction and omega-3 fatty acid supplementation. The show concludes with a mention of myFooddata.com, a nutrition information website recommended by a listener. Throughout the show, Dr. Dawn emphasizes the importance of critical thinking about medical information, considering economic drivers in healthcare, and focusing on lifestyle factors for overall health.

Broadcast from KSQD, Santa Cruz on 7-11-2024 Dr. Dawn answers a caller's question about vitamin D supplementation, explaining its importance for bone health, mood regulation, and immune function. She discusses the physiological processes involving vitamin D and recommends getting blood levels checked. A second caller asks about the safety of Stevia as a sweetener. Dr. Dawn explains the importance of examining original sources for health claims and discusses the challenges of determining causality in nutrition studies. She compares various artificial sweeteners and suggests moderation in their use. Dr. Dawn provides a health alert about a measles exposure in Santa Cruz, describing symptoms to watch for and emphasizing the importance of vaccination. She shares personal anecdotes about the dangers of measles. An email from a listener about atrial fibrillation is addressed. Dr. Dawn discusses the risks associated with atrial fibrillation, blood thinners, and the Watchman device. She emphasizes the importance of stress reduction and suggests alternatives to invasive procedures. Dr. Dawn comments on a recent retraction of a key Alzheimer's study, discussing the implications for Alzheimer's research and treatment development. A new development in baby formula is discussed, involving genetically modified plants producing human milk oligosaccharides for improved infant nutrition. Dr. Dawn responds to an email about lipoprotein A and cardiovascular risk, discussing risk factors, the importance of inflammation reduction and omega-3 fatty acid supplementation. The show concludes with a mention of myFooddata.com, a nutrition information website recommended by a listener. Throughout the show, Dr. Dawn emphasizes the importance of critical thinking about medical information, considering economic drivers in healthcare, and focusing on lifestyle factors for overall health.

Venous closure devices, GLP1-s linked to blindness and cancer, resisting the urge to do an ECG, and transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation are the topics discussed this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Venous vascular closure system vs. figure-of-eight suture following atrial fibrillation ablation: the STYLE-AF Study https://doi.org/10.1093/europace/euae105 II GLP1-s and Blindness Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255 Locke Twitter  https://x.com/doc_BLocke/status/1808972226655629610 When to Start a Statin Is a Preference-Sensitive Decision https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808 III GLP1-s and Cancer Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833 IV Screening ECG Routine Electrocardiogram Screening and Cardiovascular Disease Events in Adultshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2820721 Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP)  https://doi.org/10.1016/S0140-6736(21)01637-8 Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study) https://doi.org/10.1016/S0140-6736(21)01698-6 IV TEER for Secondary Mitral Regurgitation Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design https://doi.org/10.1002/ejhf.3247 Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3286 Jun 21, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001237 Stats Blog https://www.r-bloggers.com/2023/07/the-benjamini-hochberg-procedure-fdr-and-p-value-adjusted-explained/ You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Retractable sports fields are nothing new – but in Spain, they've found an incredibly innovative new way of storing and caring for the country's most revered plot of grass, a new, implantable light therapy could promote better healing in those suffering from spinal cord injuries, and on This Day in History - The Transcontinental Express makes its cross country journey in 83 hours. Retractable Sports Field (GNN) Implantable Light Therapy (AIChE) (GNN) Transcontinental Express (History) (The Historical Marker Database) Learn more about your ad choices. Visit megaphone.fm/adchoices